10:25 AM EST, 03/08/2024 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Friday it dosed the first subjects in a phase 1/2a study of its experimental ARO-DM1 treatment of type 1 myotonic dystrophy, the most common adult-onset muscular dystrophy.

The study will evaluate single and multiple ascending doses of ARO-DM1 in up to 48 patients, the company said.

Patients with type 1 myotonic dystrophy have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities, Arrowhead said.

The company's shares were up more than 4% in recent trading.

Price: 34.76, Change: +1.56, Percent Change: +4.70